当前位置: 首页 >> 检索结果
61. Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis.
作者: Kathryn Maitland.;San Maurice Ouattara.;Hadiza Sainna.;Abdullahi Chara.;Oluwakemi F Ogundipe.;Temmy Sunyoto.;M Hamaluba.;Peter Olupot-Olupot.;Florence Alaroker.;Roisin Connon.;Amadou Saidou Maguina.;William Okiror.;Denis Amorut.;Eric Mwajombo.;Emmanuel Oguda.;Christabel Mogaka.;Céline Langendorf.;Juan Emmanuel Dewez.;Iza Ciglenecki.;Diana M Gibb.;Matthew E Coldiron.;Roberta Petrucci.;Elizabeth C George.; .
来源: N Engl J Med. 2025年393卷13期1257-1268页
International recommendations advise against the use of intravenous rehydration therapy in children with severe acute malnutrition because of the concern about fluid overload, but evidence to support this concern is lacking. Given the high mortality associated with the current recommendations, the adoption of intravenous rehydration strategies might improve outcomes.
62. Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B.
作者: Ulrike M Reiss.;Andrew M Davidoff.;Edward G D Tuddenham.;Pratima Chowdary.;Jenny McIntosh.;Vincent Muczynski.;Malo Journou.;Giulia Simini.;Lydia Ireland.;Saira Mohamed.;Anne Riddell.;Arnulfo J Pie.;Andrew Hall.;Alberto Quaglia.;Sarah Mangles.;Johnny Mahlangu.;Kristina Haley.;Michael Recht.;Yu-Min Shen.;Kathleen G Halka.;Gail Fortner.;Christopher L Morton.;Zhengming Gu.;Randall T Hayden.;Ellis J Neufeld.;Victoria I Okhomina.;Guolian Kang.;Amit C Nathwani.
来源: N Engl J Med. 2025年392卷22期2226-2234页
Adeno-associated virus (AAV)-mediated gene therapy has emerged as a promising treatment for hemophilia B. Data on safety and durability from 13 years of follow-up in a cohort of patients who had been successfully treated with scAAV2/8-LP1-hFIXco gene therapy are now available.
63. Bedaquiline Activity against Leprosy.
作者: Abdoulaye Fomba.;Fadima C Haidara.;Mamoudou Kodio.;Catherine Arama.;Emmanuelle Cambau.;Aurélie Chauffour.;Nicolas Veziris.;Bettina E Broeckling.;Alaine K Warren.;Bertrand Cauchoix.;Alexandre Alcaïs.;Laurent Marsollier.;Henri Assé.;Mary Jackson.;Samba Ousmane Sow.;Ousmane Faye.;Vincent Jarlier.;Stewart T Cole.;Charlotte Avanzi.;Alexandra Aubry.;Roch C Johnson.
来源: N Engl J Med. 2025年392卷21期2174-2176页 64. Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
作者: Eleftherios P Mamounas.;Hanna Bandos.;Julia R White.;Thomas B Julian.;Atif J Khan.;Simona F Shaitelman.;Mylin A Torres.;Frank A Vicini.;Patricia A Ganz.;Susan A McCloskey.;Peter C Lucas.;Nilendu Gupta.;X Allen Li.;Beryl McCormick.;Benjamin Smith.;Rahul D Tendulkar.;Vivek S Kavadi.;Koji Matsumoto.;Samantha Andrews Seaward.;William J Irvin.;Jolinta Y Lin.;Robert W Mutter.;Thierry M Muanza.;Jannifer Stromberg.;Reshma Jagsi.;Anna C Weiss.;Walter J Curran.;Norman Wolmark.
来源: N Engl J Med. 2025年392卷21期2113-2124页
The benefit of regional nodal irradiation in the treatment of breast cancer is well established for patients with pathologically positive axillary nodes, but whether it is also beneficial for patients whose nodes become pathologically tumor free (ypN0) after neoadjuvant chemotherapy remains unclear.
65. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
作者: Elena Elez.;Takayuki Yoshino.;Lin Shen.;Sara Lonardi.;Eric Van Cutsem.;Cathy Eng.;Tae Won Kim.;Harpreet Singh Wasan.;Jayesh Desai.;Fortunato Ciardiello.;Rona Yaeger.;Timothy S Maughan.;Van K Morris.;Christina Wu.;Tiziana Usari.;Robert Laliberte.;Samuel S Dychter.;Xiaosong Zhang.;Josep Tabernero.;Scott Kopetz.; .
来源: N Engl J Med. 2025年392卷24期2425-2437页
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E-mutated metastatic colorectal cancer, an aggressive subtype with a poor prognosis, was compared with standard care (chemotherapy with or without bevacizumab) in an open-label, phase 3 trial, which showed significance regarding one of the two primary end points, objective response according to blinded independent central review (odds ratio for EC+mFOLFOX6 vs. standard care, 2.44; one-sided P<0.001). This result led to accelerated Food and Drug Administration approval of this investigational combination therapy for BRAF V600E-mutated metastatic colorectal cancer, including as first-line therapy. Data on progression-free survival (the second primary end point) and an updated interim analysis of overall survival are now available.
68. Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.
作者: Robert J Lentz.;Katherine Frederick-Dyer.;Virginia B Planz.;Tatsuki Koyama.;Matthew C Aboudara.;Sameer K Avasarala.;Jonathan D Casey.;George Z Cheng.;Pierre-François D'Haese.;Jennifer D Duke.;Eric L Grogan.;Todd C Hoopman.;Joyce Johnson.;James M Katsis.;Jonathan S Kurman.;See-Wei Low.;Kamran Mahmood.;Otis B Rickman.;Lance Roller.;Cristina Salmon.;Samira Shojaee.;Briana Swanner.;Momen M Wahidi.;Charla Walston.;Gerard A Silvestri.;Lonny Yarmus.;Najib M Rahman.;Fabien Maldonado.; .
来源: N Engl J Med. 2025年392卷21期2100-2112页
Each year, millions of pulmonary nodules are identified incidentally or through lung cancer screening, and many involve biopsy to distinguish cancer from benign processes. Both navigational bronchoscopy and computed tomography-guided transthoracic needle biopsy are commonly used in patients undergoing biopsies of peripheral pulmonary nodules, but the relative diagnostic accuracy of these two approaches is unclear.
69. Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease.
作者: Kiran Musunuru.;Sarah A Grandinette.;Xiao Wang.;Taylor R Hudson.;Kevin Briseno.;Anne Marie Berry.;Julia L Hacker.;Alvin Hsu.;Rachel A Silverstein.;Logan T Hille.;Aysel N Ogul.;Nancy A Robinson-Garvin.;Juliana C Small.;Sarah McCague.;Samantha M Burke.;Christina M Wright.;Sarah Bick.;Venkata Indurthi.;Shweta Sharma.;Michael Jepperson.;Christopher A Vakulskas.;Michael Collingwood.;Katie Keogh.;Ashley Jacobi.;Morgan Sturgeon.;Christian Brommel.;Ellen Schmaljohn.;Gavin Kurgan.;Thomas Osborne.;He Zhang.;Kyle Kinney.;Garrett Rettig.;Christopher J Barbosa.;Sean C Semple.;Ying K Tam.;Cathleen Lutz.;Lindsey A George.;Benjamin P Kleinstiver.;David R Liu.;Kim Ng.;Sadik H Kassim.;Petros Giannikopoulos.;Mohamad-Gabriel Alameh.;Fyodor D Urnov.;Rebecca C Ahrens-Nicklas.
来源: N Engl J Med. 2025年392卷22期2235-2243页
Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated 50% mortality in early infancy, we immediately began to develop a customized lipid nanoparticle-delivered base-editing therapy. After regulatory approval had been obtained for the therapy, the patient received two infusions at approximately 7 and 8 months of age. In the 7 weeks after the initial infusion, the patient was able to receive an increased amount of dietary protein and a reduced dose of a nitrogen-scavenger medication to half the starting dose, without unacceptable adverse events and despite viral illnesses. No serious adverse events occurred. Longer follow-up is warranted to assess safety and efficacy. (Funded by the National Institutes of Health and others.).
70. Longitudinal Changes in Airway Mucus Plugs and FEV1 in COPD.
作者: Sofia K Mettler.;Pietro Nardelli.;Monica Iturrioz Campo.;Rubén San José Estépar.;Padma P Manapragada.;Mostafa Abozeed.;Muhammad Usman Aziz.;Mohd Zahid.;Scott Grumley.;Hrudaya P Nath.;Andrew Yen.;Sushilkumar Sonavane.;Christian F Clarenbach.;Wei Wang.;Carrie L Pistenmaa.;George R Washko.;Raúl San José Estépar.;Michael H Cho.;Alejandro A Diaz.; .; .
来源: N Engl J Med. 2025年392卷19期1973-1975页 71. Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
作者: Victor Musiime.;Mutsa Bwakura-Dangarembizi.;Alexander J Szubert.;Vivian Mumbiro.;Hilda A Mujuru.;Cissy M Kityo.;Abbas Lugemwa.;Katja Doerholt.;Chishala Chabala.;Shafic Makumbi.;Veronica Mulenga.;Helen McIlleron.;David Burger.;Eva Natukunda.;Clare Shakeshaft.;Kyomuhendo Jovia Linda.;Kusum Nathoo.;Lara Monkiewicz.;Ibrahim Yawe.;Monica Kapasa.;Mary Nyathi.;Joyce Lungu.;Bwendo Nduna.;Wedu Ndebele.;Annabelle South.;Mwate Mwamabazi.;Godfrey Musoro.;Anna Griffiths.;Khozya Zyambo.;Rashidah Nazzinda.;Kevin Zimba.;Yingying Zhang.;Simon Walker.;Anna Turkova.;A Sarah Walker.;Alasdair Bamford.;Diana M Gibb.; .
来源: N Engl J Med. 2025年392卷19期1917-1932页
Children living with human immunodeficiency virus (HIV) have limited options for second-line antiretroviral therapy (ART).
72. Loss of Subsidized Drug Coverage and Mortality among Medicare Beneficiaries.
作者: Eric T Roberts.;Jessica Phelan.;Aaron L Schwartz.;Ellen Meara.;Dominic Ruggiero.;Lilly Estenson.;Rachel M Werner.;José F Figueroa.
来源: N Engl J Med. 2025年392卷20期2025-2034页
A total of 14 million Medicare beneficiaries receive the Low-Income Subsidy (LIS), which reduces cost sharing in Medicare Part D. Losing the LIS may impede medication access and affect mortality.
74. BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection.
作者: Alexander C Schmidt.;Lee Fairlie.;Elizabeth Hellström.;Angelique Luabeya Kany Kany.;Keren Middelkoop.;Kogieleum Naidoo.;Gonasagrie Nair.;Anele Gela.;Elisa Nemes.;Thomas J Scriba.;Amy Cinar.;Nicole Frahm.;Robin Mogg.;David Kaufman.;Michael W Dunne.;Mark Hatherill.; .
来源: N Engl J Med. 2025年392卷18期1789-1800页
In a previous phase 2 trial, bacille Calmette-Guérin (BCG) revaccination was not shown to provide protection from primary Mycobacterium tuberculosis infection but prevented sustained M. tuberculosis infection, defined by an initial conversion on a QuantiFERON-TB (QFT) test (an interferon-γ release assay) from negative to positive, followed by two additional positive QFT tests at 3 and 6 months after the initial conversion (a secondary end point). A vaccine efficacy of 45% (95% confidence interval [CI], 6 to 68) was observed.
75. The IARC Perspective on the Effects of Policies on Reducing Alcohol Consumption.
作者: Susan M Gapstur.;Daniela Mariosa.;Luciana Neamtiu.;Suzanne T Nethan.;Jürgen Rehm.;Taisia Huckle.;David H Jernigan.;Elizabeth A O'Connor.;Mindaugas Štelemėkas.;Peter Allebeck.;Sawitri Assanangkornchai.;Nicholas Carah.;Surasak Chaiyasong.;Samantha Cukier.;The Son Dao.;Rijo M John.;Richard Matzopoulos.;Petra S Meier.;Paula O'Brien.;Guillermo Paraje.;Robin Room.;Claire Wilkinson.;Norman D Maldonado.;Tim Stockwell.;Maria Neufeld.;Dag Rekve.;Béatrice Lauby-Secretan.
来源: N Engl J Med. 2025年392卷17期1752-1759页 76. Nonoperative Management of Mismatch Repair-Deficient Tumors.
作者: Andrea Cercek.;Michael B Foote.;Benoit Rousseau.;J Joshua Smith.;Jinru Shia.;Jenna Sinopoli.;Jill Weiss.;Melissa Lumish.;Lindsay Temple.;Miteshkumar Patel.;Callahan Wilde.;Leonard B Saltz.;Guillem Argiles.;Zsofia Stadler.;Oliver Artz.;Steven Maron.;Geoffrey Ku.;Ping Gu.;Yelena Y Janjigian.;Daniela Molena.;Gopa Iyer.;Jonathan Coleman.;Wassim Abida.;Seth Cohen.;Kevin Soares.;Mark Schattner.;Vivian E Strong.;Rona Yaeger.;Philip Paty.;Marina Shcherba.;Ryan Sugarman.;Paul B Romesser.;Alice Zervoudakis.;Avni Desai.;Neil H Segal.;Imane El Dika.;Maria Widmar.;Iris Wei.;Emmanouil Pappou.;Gerard Fumo.;Santiago Aparo.;Mithat Gonen.;Marc Gollub.;Vetri S Jayaprakasam.;Tae-Hyung Kim.;Julio Garcia Aguilar.;Martin Weiser.;Luis A Diaz.
来源: N Engl J Med. 2025年392卷23期2297-2308页
Among patients with mismatch repair-deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this approach can be extended to all early-stage dMMR solid tumors, regardless of tumor site, is unknown.
78. Performance of Dialysis Facilities after Health-Equity Scoring Incentive.
作者: Kalli G Koukounas.;Meehir N Dixit.;Rebecca Thorsness.;Rachel E Patzer.;Adam S Wilk.;Kelsey M Drewry.;Rajnish Mehrotra.;Maricruz Rivera-Hernandez.;David J Meyers.;Daeho Kim.;Ankur D Shah.;Christopher H Schmid.;Amal N Trivedi.
来源: N Engl J Med. 2025年392卷16期1657-1659页 79. Tumor-Infiltrating Clonal Hematopoiesis.
作者: Oriol Pich.;Elsa Bernard.;Maria Zagorulya.;Andrew Rowan.;Constandina Pospori.;Ramy Slama.;Hector Huerga Encabo.;Jennifer O'Sullivan.;Despoina Papazoglou.;Panayiotis Anastasiou.;Chrysante S Iliakis.;Sally-Ann Clark.;Krijn K Dijkstra.;Vittorio Barbè.;Chris Bailey.;Aaron J Stonestrom.;Katey S S Enfield.;Mary Green.;Charlotte K Brierley.;Alastair Magness.;David R Pearce.;Robert E Hynds.;Rija Zaidi.;Jayant K Rane.;Ángel F Álvarez-Prado.;Kerstin Thol.;Rachel Scott.;Supreet Kaur Bola.;Elena Hoxha.;Steve K Harris.;Karl S Peggs.;Sergio A Quezada.;Allan Hackshaw.;Simone Zaccaria.;Johanna A Joyce.;Ilaria Malanchi.;Michael F Berger.;Mariam Jamal-Hanjani.;Andreas Wack.;Julian Downward.;William Grey.;Cristina Lo Celso.;Eva Grönroos.;Charles M Rudin.;Adam J Mead.;Dominique Bonnet.;Elli Papaemmanuil.;Charles Swanton.
来源: N Engl J Med. 2025年392卷16期1594-1608页
Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencies can be detected in tumors, a phenomenon we term tumor-infiltrating clonal hematopoiesis (TI-CH). The frequency of TI-CH and its effect on tumor evolution are unclear.
80. Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.
作者: .;Rosine Ali.;Jules Alonga.;Jean-Luc Biampata.;Michael Kombozi Basika.;Irina Maljkovic Berry.;Nella Bisento.;Emily Blum.;Tyler Bonnett.;Katherine Cone.;Ian Crozier.;Richard Davey.;Ali Dilu.;Lori E Dodd.;Iman Gulati.;Dennis Hruby.;Augustin Ibanda.;Francis Isse.;Sylva Sivasingana Kasareka.;Gaby Kayembe.;Richard Kojan.;Esaie Kindombe Luzolo.;H Clifford Lane.;Leader Lawanga.;Laurens Liesenborghs.;Claude Shosongo Lunghe.;Yves Lula.;Mariano Lusakibanza.;Gaston Tona Lutete.;Placide Mbala-Kingebeni.;Alejandra Miranda.;Daniel Mukadi-Bamuleka.;Gael Mukendi.;Patrick Mutombo Lupola.;Jean-Jacques Muyembe-Tamfum.;Robin Ndungunu.;Bruce Nganga.;Nsengi Ntamabyaliro.;Veronique Nussenblatt.;Imoite Omulepu.;John Omalokoho Onosomba.;Michael Proschan.;Kevin Rubenstein.;Inga Saknite.;Adam Schechner.;Kathryn Shaw-Saliba.;Billy Sivahera.;Mary Smolskis.;Amy Tillman.;Eric Tkaczyk.;Celestin Tshimanga.;Olivier Tshiani Mbaya.;Antoine Tshomba.;Freddy Yemba Unda Tshomba.;David Vallee.;Susan Vogel.;Shera Weyers.
来源: N Engl J Med. 2025年392卷15期1484-1496页
Tecovirimat is available for the treatment of mpox (formerly known as monkeypox) in Europe and the United States, on the basis of findings from efficacy studies in animals and safety evaluations in healthy humans. Evidence from randomized, controlled trials of safety and efficacy in patients with mpox is lacking.
|